(Q36757591)

16 August 2017

Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis (English)

1 reference

16 August 2017

0 references

invasive aspergillosis

1 reference

1 reference

10

Michael Hallek

1 reference

16 August 2017

2

Oliver A Cornely

1 reference

16 August 2017

Jörg Janne Vehreschild

4

object named as

Janne J Vehreschild

1 reference

16 August 2017

Maria J G T Vehreschild

5

object named as

Maria J G T Vehreschild

1 reference

16 August 2017

6

Fedja Farowski

1 reference

16 August 2017

Gudrun Würthwein

1

1 reference

16 August 2017

Mirjam N Trame

3

1 reference

16 August 2017

Carsten Müller

7

1 reference

16 August 2017

Joachim Boos

8

1 reference

16 August 2017

Georg Hempel

9

1 reference

16 August 2017

Andreas H Groll

11

1 reference

16 August 2017

language of work or name

English

0 references

publication date

18 January 2013

1 reference

Antimicrobial Agents and Chemotherapy

16 August 2017

1 reference

16 August 2017

57

1 reference

16 August 2017

4

1 reference

16 August 2017

1664-1671

1 reference

Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Phase II dose escalation study of caspofungin for invasive Aspergillosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Echinocandin antifungal drugs in fungal infections: a comparison

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Diagnosing model diagnostics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Potential for interactions between caspofungin and nelfinavir or rifampin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Caspofungin: an echinocandin antifungal agent

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Prediction of creatinine clearance from serum creatinine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

A size standard for pharmacokinetics.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

Hepatic uptake of the novel antifungal agent caspofungin

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3623320

5 September 2018

1 reference

12 December 2020

Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

1 reference

12 December 2020

Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit

1 reference

12 December 2020

Caspofungin for the treatment of less common forms of invasive candidiasis

1 reference

12 December 2020

Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations

1 reference

12 December 2020

Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants

1 reference

12 December 2020

Standardized visual predictive check versus visual predictive check for model evaluation

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.01912-12

1 reference

16 August 2017

1 reference

16 August 2017

1 reference